Skip to main content
Clinical Trials/CTRI/2019/08/020739
CTRI/2019/08/020739
Recruiting
Phase 2

A randomized controlled clinical study of karanjadi vati and rosuvastatin tablet in the management of medovridhhi with special reference to hyperlipidaemia.

ASHISH KECHE0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: E785- Hyperlipidemia, unspecified
Sponsor
ASHISH KECHE
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
ASHISH KECHE

Eligibility Criteria

Inclusion Criteria

  • 1\)Patient having Serum LDL Cholesterol Level above 190mg/dl.
  • 2\) According to NCEP ATP III, Patient having multiple (\+2\) risk factor with 10 year risk of 10% of CHD whose LDL Cholesterol goals not achieve (\>\=160mg/dl) after 12 weeks Therapeutic lifestyle changes (TLC).
  • 3\)According to NCEP ATP III, Patient having multiple (\+2\) risk factor with 10 year risk of 10% to 20% of CHD whose LDL Cholesterol goals not achieve (\>\=130mg/dl) after 12 weeks Therapeutic lifestyle changes (TLC).

Exclusion Criteria

  • 1\)Patient with Multiple (\+2\) risk factor with 10 year risk 10% of CHD, who achieve the goal of LDL Cholesterol (\<\=160mg/dl) after TLC therapy.
  • 2\)Patient with Multiple (\+2\) risk factor with 10 year risk 10% to 20% of CHD, who achieve the goal of LDL Cholesterol (\<\=130mg/dl) after TLC therapy.
  • 3\)Pregnant women and lactating mothers.
  • 4\)Patients having history of Renal Disease, Liver Disease.
  • 5\)Patients having Recently 3 month history of Heart Failure or Stroke.
  • 6\)Patients having disorders like Carcinoma etc. anywhere in the body.

Outcomes

Primary Outcomes

Not specified

Similar Trials